Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYNB NASDAQ:SNSE NASDAQ:TNFA NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYNBKyntra Bio$6.82-2.7%$7.04$4.85▼$12.60$27.61M1.037,848 shs9,951 shsSNSESensei Biotherapeutics$20.43+3.1%$28.89$5.25▼$36.76$27.40M-0.1831,171 shs40,624 shsTNFATNF Pharmaceuticals$4.33-15.6%$3.79$0.04▼$8.94$8.00M2.0432.22 million shs616,644 shsTPSTTempest Therapeutics$1.83-12.4%$1.94$1.50▼$12.23$27.10M-1.75162,074 shs270,577 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYNBKyntra Bio0.00%-1.87%-5.15%-8.46%+681,999,900.00%SNSESensei Biotherapeutics0.00%-12.69%-30.08%+124.75%+200.44%TNFATNF Pharmaceuticals-15.59%+14.85%+6.39%+11.60%-80.36%TPSTTempest Therapeutics0.00%-8.04%-18.30%-22.46%-72.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYNBKyntra Bio$6.82-2.7%$7.04$4.85▼$12.60$27.61M1.037,848 shs9,951 shsSNSESensei Biotherapeutics$20.43+3.1%$28.89$5.25▼$36.76$27.40M-0.1831,171 shs40,624 shsTNFATNF Pharmaceuticals$4.33-15.6%$3.79$0.04▼$8.94$8.00M2.0432.22 million shs616,644 shsTPSTTempest Therapeutics$1.83-12.4%$1.94$1.50▼$12.23$27.10M-1.75162,074 shs270,577 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYNBKyntra Bio0.00%-1.87%-5.15%-8.46%+681,999,900.00%SNSESensei Biotherapeutics0.00%-12.69%-30.08%+124.75%+200.44%TNFATNF Pharmaceuticals-15.59%+14.85%+6.39%+11.60%-80.36%TPSTTempest Therapeutics0.00%-8.04%-18.30%-22.46%-72.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYNBKyntra Bio 2.33HoldN/AN/ASNSESensei Biotherapeutics 2.00Hold$40.0095.79% UpsideTNFATNF Pharmaceuticals 1.00SellN/AN/ATPSTTempest Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest TNFA, TPST, SNSE, and KYNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/24/2026SNSESensei Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SNSESensei Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/20/2026SNSESensei Biotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$50.004/2/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy2/27/2026KYNBKyntra Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYNBKyntra Bio$6.44M4.29N/AN/A($7.60) per share-0.90SNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/ATNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYNBKyntra Bio$183.45M$40.460.17N/AN/A2,199.13%N/A-36.71%N/ASNSESensei Biotherapeutics-$21.08M-$16.67N/AN/AN/AN/A-83.59%-69.97%8/4/2026 (Estimated)TNFATNF Pharmaceuticals-$23.36M-$231.00N/AN/AN/AN/A-69.21%-33.98%N/ATPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-276.33%-107.60%N/ALatest TNFA, TPST, SNSE, and KYNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025SNSESensei Biotherapeutics-$0.62-$131.45-$130.83-$131.45N/AN/A5/15/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A3/30/2026Q4 2025SNSESensei Biotherapeutics-$4.81-$3.74+$1.07-$3.74($4.85) millionN/A3/30/2026Q4 2025TPSTTempest Therapeutics-$0.62-$0.62N/A-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKYNBKyntra BioN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYNBKyntra BioN/A3.613.26SNSESensei BiotherapeuticsN/A5.065.06TNFATNF PharmaceuticalsN/A0.930.93TPSTTempest TherapeuticsN/A2.502.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYNBKyntra Bio72.71%SNSESensei Biotherapeutics10.50%TNFATNF Pharmaceuticals9.64%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipKYNBKyntra Bio1.98%SNSESensei Biotherapeutics23.20%TNFATNF Pharmaceuticals0.45%TPSTTempest Therapeutics6.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYNBKyntra Bio5704.05 million3.97 millionN/ASNSESensei Biotherapeutics401.34 million1.03 millionNot OptionableTNFATNF Pharmaceuticals61.85 million1.84 millionN/ATPSTTempest Therapeutics2014.34 million13.44 millionNo DataTNFA, TPST, SNSE, and KYNB HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Tempest Therapeutics (NASDAQ:TPST) to SellMay 16 at 1:55 AM | americanbankingnews.comTempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 15 at 7:50 AM | finanznachrichten.deTempest Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14 at 4:15 PM | globenewswire.comTempest Therapeutics (TPST) Expected to Announce Earnings on TuesdayMay 10, 2026 | americanbankingnews.comTempest Presents Clinical Update at ISCT 2026 Annual MeetingMay 6, 2026 | globenewswire.comTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingApril 29, 2026 | globenewswire.comTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TApril 22, 2026 | globenewswire.comTempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsApril 14, 2026 | globenewswire.comNew Strong Buy Stocks for April 10thApril 10, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)April 1, 2026 | theglobeandmail.comTempest Reports Year End 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comTempest Therapeutics (NASDAQ:TPST) CEO Matthew Angel Acquires 231,482 SharesMarch 26, 2026 | insidertrades.comTempest Therapeutics Announces Up To $6 Million Private PlacementMarch 23, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 12, 2026 | finanznachrichten.deTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 11, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026February 26, 2026 | finanznachrichten.deTempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026February 25, 2026 | globenewswire.comTempest Therapeutics to Prioritize Development of Newly Acquired CAR T-Cell ProgramsFebruary 11, 2026 | precisionmedicineonline.comPTempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T AssetsFebruary 11, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T AssetsFebruary 5, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNFA, TPST, SNSE, and KYNB Company DescriptionsKyntra Bio NASDAQ:KYNB$6.82 -0.19 (-2.71%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$6.82 0.00 (-0.07%) As of 05/15/2026 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Sensei Biotherapeutics NASDAQ:SNSE$20.43 +0.61 (+3.08%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$21.55 +1.12 (+5.48%) As of 05/15/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.TNF Pharmaceuticals NASDAQ:TNFA$4.33 -0.80 (-15.59%) As of 05/15/2026TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Tempest Therapeutics NASDAQ:TPST$1.83 -0.26 (-12.44%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.88 +0.05 (+2.73%) As of 05/15/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
